
Clinical Microbiomics A/S and CosmosID Inc. Merge to Create the Global Leader in Microbiome Research Services
Clinical Microbiomics A/S, a microbiome bioinformatics and systems biology company, and CosmosID Inc., a leading CLIA-certified, GxP-compliant microbiome Contract Research Organization (CRO), have announced a merger to strengthen their microbiome service offerings. The new entity will improve global infrastructure comprising state-of-the-art multi-omics laboratories, advanced bioinformatics capabilities, applied Artificial Intelligence, and expertise in integrative systems biology, all in line with GxP standards. The microbiome has been an area of significant scientific interest and pharmaceutical development in recent years, with the first microbiome based therapeutics recently approved by the FDA and several companies looking at the use of the microbiome for clinical diagnostic purposes. The merger should allow the combined companies to better compete against competitive microbiome CROs such as Microba and OraSure’s Diversigen business unit.
Anders Grøn, CEO of Clinical Microbiomics, highlighted the significance of this merger, emphasizing the company’s commitment to innovation and its role in pushing the boundaries of microbiome research. The aim is to empower microbiome scientists with innovative tools, concepts, and insights that will facilitate groundbreaking discoveries. Grøn noted that the microbiome represents the next frontier in healthcare, and the newly-formed entity is dedicated to supporting clients and partners in leading the way in this field.
One of the central challenges in microbiome research is the standardization of sampling, data generation, and analysis. The integration of Clinical Microbiomics and CosmosID offers a unique opportunity to accelerate this standardization, ensuring the reliability and comparability of results. The merger allows access to GxP laboratories with rapid turnaround times and adherence to regulatory standards. This is complemented by an advanced analytical platform developed at the global center of expertise for advanced bioinformatics and integrative systems biology.
This merger follows the previous merger between Clinical Microbiomics and MS-Omics, a prominent metabolomics company, reflecting the company’s trajectory of rapid expansion and dedication to driving microbiome innovations. The new company will initially be known as “CMC” (Clinical Microbiomics, MS-Omics, CosmosID) until a new brand is unveiled in 2024 to represent the shared strategic vision of the company. CMC will be headquartered in Copenhagen, Denmark, with over 100 employees working in scientific, operational, and commercial roles across three laboratory and bioinformatics sites in Europe and North America. Anders Grøn, the former CEO of Clinical Microbiomics will be the CEO of the new combined organization.